Jyong Biotech Ltd Dossier
Qualitative Analysis
Business overview
Jyong Biotech Ltd. (NASDAQ: MENS) is a Taiwan-based, science-driven clinical-stage biotechnology holding company founded in 2002. The company is dedicated to the research, development, and commercialization of innovative, plant-derived (botanical) drugs primarily targeting unmet medical needs in urinary system diseases. Its core pipeline operates through subsidiaries such as Health Ever Bio-Tech and Genvace, with an initial commercial focus on the United States, European Union, and Asian markets (including Taiwan and mainland China). The company's lead drug candidate is MCS-2 (Botreso), an oral botanical drug developed for the treatment of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). Other pipeline candidates include PCP (MCS-8) for prostate cancer prevention, which is in Phase II clinical development, and IC for interstitial cystitis/bladder pain syndrome, which is in the preclinical stage.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the development of lead candidate MCS-2 (BOTRESO) to meet FDA requirements by demonstrating comparability between the original active pharmaceutical ingredient (API-1) and a new source (API-2) through a U.S. pharmacokinetic study and a subsequent Phase III trial.
Expected impact: Securing FDA approval to access the premium U.S. market for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Engaging in discussions with major pharmaceutical companies to co-develop and co-fund the Phase III oncology program for MCS-8 (PCP) following successful Phase II trials in Taiwan.
Expected impact: Allows the company to advance a large-scale preventative Phase III trial and pursue strategic out-licensing models without diverting core resources.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides the necessary commercial infrastructure, hospital/clinic sales network, and local regulatory expertise to navigate South Korea's regulatory and reimbursement landscape for MCS-2.
Terms: Non-binding Letter of Intent (LOI) signed on November 24, 2025; definitive financial terms are subject to negotiation and due diligence.
Initiates due diligence to define the regulatory and commercial pathway for MCS-2 in the rapidly aging Vietnamese pharmaceutical market.
Terms: Non-binding Memorandum of Understanding (MOU) signed on December 4, 2025; definitive terms are subject to ongoing discussions.